Andrew Blauvelt, Dermatology Meeting News 2021: Abrocitinib JADE REGIMEN Trial
It was a pleasure to speak with Dr Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the JADE REGIMEN Phase 3 trial (NCT03627767) investigating abrocitinib in patients with atopic dermatitis.
The abstract entitled ‘Abrocitinib Induction, Randomized Withdrawal and Response Recapture With Rescue Therapy in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the JADE REGIMEN Phase 3 Trial’ was presented at AAD VMX, 23-25 April 2021.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.
- What is the rationale for the use of abrocitinib in the treatment of adults with moderate to severe atopic dermatitis? (0:14)
- Could you tell us about the unique design of the JADE REGIMEN Phase 3 study? (0:55)
- What was the response to abrocitinib in the induction, maintenance and rescue periods? (3:09)
- What was the safety profile of abrocitinib, and how can adverse events be minimized? (4:52)
- What are the significance of these findings in terms of the evolving treatment paradigm for atopic dermatitis? (6:18)
Disclosures: Dr. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Atopic Dermatitis
Amy Paller, Dermatology Meeting News 2023: The efficacy of dupilumab in children with atopic dermatitis
Dupilumab is a monoclonal antibody approved for use in patients with atopic dermatitis that is not well controlled with topical treatments, or who are unable to use topical treatments. It was a pleasure to talk with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA) about the […]
Amy Paller, Dermatology Meeting News 2023: Current treatment paradigm for atopic dermatitis in children
Atopic dermatitis is a chronic skin disorder causing inflammation, redness and irritation of the skin, and usually begins in childhood. touchIMMUNOLOGY caught up with Prof Amy Paller (Northwestern University Feinberg School of Medicine; Lurie Children’s Hospital of Chicago, Chicago, IL, USA), to discuss the current treatment paradigm for atopic dermatitis in children, and factors that […]
Melinda Gooderham, Dermatology Meeting News 2023: Abrocitinib efficacy in atopic dermatitis by baseline disease severity – findings from an interim analysis of JADE EXTEND
JADE-EXTEND (NCT03422822) is a phase 3 long-term extension study investigating the efficacy and safety of abrocitinib in atopic dermatitis. In this touchIMMUNOLOGY interview, we caught up with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, Canada) around her interim analysis of JADE-EXTEND, looking at efficacy by baseline disease severity. The abstract ‘Influence of Baseline Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!